von Willebrand factor activity and activated partial thromboplastin time as proxy biomarkers for coagulopathies in women with menorrhagia in Zambia: a case-control study

Munsanje, Miyoba Melinda; Kaile, Trevor; Kowa, Sumbukeni; Sinkala, Musalula; Simakando, Marah; Ndhlovu, Jacob; Chiluba, Brian Chanda

doi:10.11604/pamj.2021.39.13.13742

Cited by 1 publication

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prolonged APTT indicates decreased or inactive coagulation factors, von Willebrand factor [7], prekallikrein [8], decreased activity of high molecular weight kininogen [9], and the presence of a lupus anticoagulant (LA) [10], [11]. Specific diseases and conditions include von Willebrand disease, hemophilia, disseminated intravascular syndrome, and Vitamin K deficiency [12], [13].…”

Section: Introductionmentioning

confidence: 99%

False Prolongation of Activated Partial Thromboplastin Time with Aminoglycoside Antimicrobial Agents: A Case Report

Doi,

Osawa,

Ozaki

et al. 2023

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: Activated partial thromboplastin time (APTT) is a clotting time assay for screening bleeding tendency, evaluating coagulation factor production capacity, assessing preoperatively, monitoring anticoagulant drugs, and searching for blood coagulation abnormalities such as hemophilia and antiphospholipid syndrome. CASE PRESENTATION: Here, we present a 77-year-old male patient with dyspnea who was suspected to have a drug-resistant Pseudomonas aeruginosa infection and pulmonary mycosis. The patient had no history of bleeding tendencies or anticoagulant medication use. The laboratory test results revealed an abnormally prolonged activated partial thromboplastin time (APTT) of 120.3 s using the Coagpia® APTT-N reagent. The APTT test is frequently used to evaluate blood clotting function and assess for bleeding disorders. Prolonged APTT can indicate coagulation factor deficiencies or the presence of certain conditions such as von Willebr and disease, hemophilia, and disseminated intravascular syndrome. However, APTT standardization has not been achieved, causing discrepancies in test results due to variations in the reagents used. The prolonged APTT, in this case, was initially suspected to be caused by contamination or other artifacts, but repeat blood collections and cross-mixing tests revealed the Coagpia® APTT-N reagent as the cause of false prolongation. The reagent was changed to HemosIL SynthASil APTT, which revealed a normal APTT result. The patient had been receiving the aminoglycoside antimicrobial agent tobramycin, and the blood sample taken at the peak tobramycin level demonstrated the longest APTT time. The APTT shortened over time, corresponding to the decrease in tobramycin blood levels. CONCLUSION: Overall, this paper reports a case of false APTT prolongation due to a specific APTT reagent in the presence of aminoglycoside antimicrobial agents. The findings underscore the difficulties in standar PTT testing and the importance of considering reagent performance characteristics in result interpretations.

show abstract